These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Time-critical administration of corticosteroid rescue therapy for COVID-19 pneumonitis in a ward-based patient with chronic obstructive pulmonary disease. Kuzeva A; Dost S; Lams B; Agarwal S; Furmedge DS Br J Hosp Med (Lond); 2020 Jul; 81(7):1-4. PubMed ID: 32730151 [No Abstract] [Full Text] [Related]
45. Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report. Meazza Prina M; Martini F; Bracchi F; Di Mauro D; Fargnoli A; Motta M; Giussani C; Gobbin G; Taverna M; D'Alessio A BMC Infect Dis; 2021 Aug; 21(1):811. PubMed ID: 34388982 [TBL] [Abstract][Full Text] [Related]
46. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better? Bendjelid K; Giraud R; Von Düring S Anaesth Crit Care Pain Med; 2020 Aug; 39(4):451-452. PubMed ID: 32653550 [No Abstract] [Full Text] [Related]
47. A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection? Sereno M; Gutiérrez-Gutiérrez G; Sandoval C; Falagan S; Jimenez-Gordo AM; Merino M; López-Menchaca R; Martínez-Martin P; Roa S; Casado E Lung Cancer; 2020 Jul; 145():213-215. PubMed ID: 32389426 [No Abstract] [Full Text] [Related]
48. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? Opoka-Winiarska V; Grywalska E; Roliński J BMC Med; 2020 Jul; 18(1):214. PubMed ID: 32664932 [TBL] [Abstract][Full Text] [Related]
49. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. Hakim NN; Chi J; Olazagasti C; Liu JM Exp Biol Med (Maywood); 2021 Jan; 246(1):5-9. PubMed ID: 32972235 [TBL] [Abstract][Full Text] [Related]
50. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. Imazio M; Brucato A; Lazaros G; Andreis A; Scarsi M; Klein A; De Ferrari GM; Adler Y J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):625-629. PubMed ID: 32658005 [TBL] [Abstract][Full Text] [Related]
52. Severe Pediatric COVID-19 Pneumonia Treated With Adjuvant Anakinra. Stubbs LA; Szafron V; Forbes LR; Musick MA; Gillispie AE; Sauer HE; Smith VR; Fasipe TA; Munoz FM; Tejtel KS; Silva-Carmona M; Vogel TP; Muscal E Hosp Pediatr; 2022 May; 12(5):e162-e170. PubMed ID: 35237791 [TBL] [Abstract][Full Text] [Related]
53. An elevated HScore is associated with poor clinical outcomes in COVID-19. Benavente R; Peña C; Cid A; Cabello N; Bustamante P; Álvarez M; Henríquez E; Soto A; Rubilar E Rev Med Chil; 2023 Feb; 151(1):15-22. PubMed ID: 37906742 [TBL] [Abstract][Full Text] [Related]
54. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Balkhair A; Al-Zakwani I; Al Busaidi M; Al-Khirbash A; Al Mubaihsi S; BaTaher H; Al Aghbari J; Al Busaidi I; Al Kindi M; Baawain S; Al Alawi A; Al Lawati A; Al Rawahi B; Al-Baimani K; Al Zidi K; Elfatih N; Dawud B; John B; Rehman F; Yousif F; Al Khadouri G; Saber I; Lal J; Gargouri M; Al-Ward M; AbuDraz N; Al Ruqeishi S; Kumar S; Abdelmottaleb W; Al-Naamani Z; Bin Nazar Z; Balkhair O Int J Infect Dis; 2021 Feb; 103():288-296. PubMed ID: 33217576 [TBL] [Abstract][Full Text] [Related]
55. Effect of COVID-19 on anakinra-induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis. Vagrecha A; Patel HB; Mamdouhi T; Acharya S; Appiah-Kubi A; Aygun B; Vlachos A; Wolfe LC; Lipton JM; Cron RQ; Fein Levy C Pediatr Blood Cancer; 2021 Jun; 68(6):e28897. PubMed ID: 33442938 [No Abstract] [Full Text] [Related]
56. [Secondary hemophagocytic lymphohistiocytosis and cytokine release syndrome in COVID-19, the same or different entities?]. Alfaro-Murillo A; Lazo-Paéz G Rev Chilena Infectol; 2021 Apr; 38(2):271-278. PubMed ID: 34184718 [TBL] [Abstract][Full Text] [Related]
57. Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality. Ardern-Jones MR; Stammers M; Phan HT; Borca F; Koutalopoulou A; Teo Y; Batchelor J; Smith T; Duncombe AS Clin Med (Lond); 2021 Sep; 21(5):e543-e547. PubMed ID: 34389636 [TBL] [Abstract][Full Text] [Related]
58. Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression. Lubnow M; Schmidt B; Fleck M; Salzberger B; Müller T; Peschel G; Schneckenpointner R; Lange T; Hitzenbichler F; Kieninger M; Lunz D; Graf B; Brochhausen C; Weber F; Lüke F; Peterhoff D; Schuster P; Hiergeist A; Offner R; Hehr U; Wallner S; Hanses F; Schmid S; Weigand K; Geismann F; Poeck H; Pukrop T; Evert M; Gessner A; Burkhardt R; Herr W; Maier LS; Heudobler D Int J Infect Dis; 2021 Feb; 103():624-627. PubMed ID: 33412272 [TBL] [Abstract][Full Text] [Related]
59. Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children. Charlesworth JEG; Wilson S; Qureshi A; Blanco E; Mitchell A; Segal S; Kelly D; Weitz J; O'Shea D; Bailey K; Kavirayani A Pediatr Blood Cancer; 2021 Sep; 68(9):e29102. PubMed ID: 34114322 [TBL] [Abstract][Full Text] [Related]
60. Etoposide-based therapy for severe forms of COVID-19. Hamizi K; Aouidane S; Belaaloui G Med Hypotheses; 2020 Sep; 142():109826. PubMed ID: 32416415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]